## **PROXY FORM**

**Proxy** 

in accordance with Chapter 7 Section 54 (a) of the Swedish Companies Act

I hereby appoint the proxy stated below, or whomever he or she may appoint, to vote on my behalf for all my shares in Calliditas Therapeutics AB (publ), Reg. No. 56659-9766, at the extraordinary general meeting of Calliditas Therapeutics AB (publ) on 3 March 2020.

Name of the proxy	Personal identity number/Date of birth
	-
Address	
Postal code and city	Telephone number
Ciamatuma hurtha ahamahaldan	
Signature by the shareholder	
Signature by the shareholder  Name of the shareholder	Personal identity number/Date of birth/Registration number
	Personal identity number/Date of birth/Registration number
	Personal identity number/Date of birth/Registration number
Name of the shareholder	
	Personal identity number/Date of birth/Registration number  Telephone number
Name of the shareholder	
Name of the shareholder	
Name of the shareholder  Place and date	
Name of the shareholder	

\*If signing for a company, a clarification of signature shall be included above and an up to date certificate of registration (or the equivalent) shall be enclosed to the completed proxy form.

Please note that a shareholder shall give the company notice of attendance – as set out in the notice convening the meeting – even if the shareholder intends to exercise his or her voting rights through a proxy.

The completed proxy form in original (with any enclosures) should be sent to Calliditas Therapeutics, "General meeting", Kungsbron 1, C8, SE-111 22 Stockholm, together with the notice of attendance. For the avoidance of doubt, if the shareholder does *not* intend to exercise his or her voting rights through a proxy, the proxy form does not have to be sent to the company.

## Processing of personal data

For information on how your personal data is processed, see the integrity policy that is available at Euroclear's webpage www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf.